Bli medlem
Bli medlem

Du är här

2015-04-24

Revenio Group Corporation: Interim Report January 1 - March 31, 2015: Strong first quarter - considerable growth in net sales and operating profit

Revenio Group Corporation Stock Exchange Release April 24, 2015 at 9:00

Revenio Group Corporation Interim Report, January 1-March 31, 2015

Revenio Group Corporation is adopting the publication procedure enabled by the
Financial Supervisory Authority's Regulations and guidelines 7/2013
(Disclosure obligation on issuers) and is publishing its Interim Report for
January-March 2015 as an appendix to this stock exchange release. This stock
exchange release is a summary of the Revenio Group Corporation's Interim
Report for January-March 2015. The Interim Report can be read in full in the
PDF appendix to this release. The Interim Report is also available on
Revenio's website:http://www.revenio.fi.

STRONG FIRST QUARTER FOR REVENIO

- CONSIDERABLE GROWTH IN NET SALES AND OPERATING PROFIT

January-March in brief, continuing Group functions:

* Net sales EUR 4.6 (3.7) million, growth 24.4%
* Operating profit EUR 1.4 (1.1) million, growth 26.8%
* Undiluted earnings per share 0.16 (0.12), diluted earnings per share 0.15
(0.12)
* Cash and cash equivalents EUR 5.1 (4.0) million
* Equity ratio 69.7 (63.7)%
* During the review period, in February, the Group announced the licensing of
technologies related to the detection of asthma and skin cancer and the
intention to commercialize these technologies. The projects have proceeded
according to plan
* The sale of Boomeranger Boats Oy in February supports the Group's focus on
health technology
* Revenio's NASDAQ OMX ICB classification changed to Health Care on March 3,
2015
* From the beginning of May, CEO Olli-Pekka Salovaara will temporarily
relocate to the United States, which reflects the central role of this
market in the health technology industry
* The growth of probe sales continued strong, amounting to 2.3 (1.8) million
pcs, up by 27% from the previous year
* During the review period, we made headway in the clinical trials related to
the Icare HOME tonometer's FDA license in the United States

Key figures, Continuing operations, MEUR:

-----------------------------------------------------------------------------------------
| Key Figures, MEUR: |
| 1-3/2015 1-3/2014 Change-% |
| Net sales, Group 4.6 3.7 24.4 |
| Operating profit, Group 1.4 1.1 26.8 |
| Net sales, Health Tech 4.6 3.7 24.4 |
| Operating profit, Health Tech 1.7 1.4 23.3 |
| Undiluted earnings per share 0.16 0.12 14.3 |
| Diluted earnings per share 0.15 0.12 15.5 |
| Cash flow from operating activities 3.1 0.1 3000.0 |
| 31 March 2015 31 March 2014 Change, %- point |
| Equity ratio-% 69.7 63,7 6.0 |
| Gearing-% -38.5 -14,7 23.8 |
-----------------------------------------------------------------------------------------
Financial guidance

The net sales and operating profit of Icare are expected to grow from last
year. Investments in new business operations related to health tech, which
have an impact on consolidated operating profit and cash flow. No significant
investments will be made in 2015.

Outlook

In the next few years, health care will face considerable challenges
everywhere in the world. Aging populations, the proliferation of chronic
diseases, increasing inequality and, most of all, the increasing costs of
health care, will force national economies to look for more efficient ways to
treat and prevent diseases having a major impact on public health. Screening
and the related technologies play a key role in this development. The
screening market is global, and too little screening is still performed in
relation to the potential benefits. In contrast to the development of new
pharmaceuticals, screening does not require prolonged clinical trials;
rather, the benefits can be achieved with quick and precise referral for
treatment.

Revenio's role in the screening process is to produce simple and easy-to-use
methods, devices and technologies to replace old-fashioned and inefficient
operating models.

Olli-Pekka Salovaara, President and CEO, comments on the first quarter
results:

"As expected, the first quarter of 2015 got off to a strong start. Our net
sales grew by 24.4% and we enjoyed excellent profitability, despite
investments in new growth areas. The considerable strengthening of the US
dollar has a positive impact on our result as we exchanged USD deposits for
euros in 2014 and during the first quarter of 2015.

From March 2015, Revenio is a health tech group according to the NASDAQ OMX
ICB classification, with Health Care as its official industry classification.
Our goal is global market leadership in eye pressure measurement products. In
the evolution of technologies related to the measurement of eye pressure,
Icare is in the process of displacing competing products based on traditional
methods, which has enabled us to win market shares in our key markets. Our
new health tech R&D projects announced during the review period tackle global
public health challenges in which the common denominator is a pressing need
to make cost savings in health care via preventive measures. We will
revolutionize these markets by introducing leading screening technologies
used by health care professionals everywhere in the world. We are
systematically launching new, easy-to-use and cost-effective products for
screening and monitoring for diseases with a major impact on public health.

In February, we sold the entire share capital of Technology and Services
segment subsidiary Boomeranger Boats Oy, which had been transferred to
discontinued operations. We are focusing on health technology in accordance
with our strategy, and the sale of a company not operating in this core field
of business supports the realization of the strategy.

Icare's tonometers sold well in all key markets during the review period. The
sales of Icare HOME tonometer have picked up speed. According to feedback
from experts, there is clear demand for this product that will change current
treatment practice. In the United States, the clinical trials related to our
FDA license application have progressed well during the review period, but it
is still too early to say when we will be in a position to file the
application. Probe sales have maintained a strong growth, which provides a
stable and constantly expanding foundation for Icare's device sales.

For its part, the Oscare Sono(TM) osteoporosis detection device has attracted
a great deal of interest in the market during the review period. The device
is an excellent screening method for DXA, which represents the current
standard. We will therefore once again help society to save on costs, as
patients needing more detailed examinations can be referred to further tests
on the basis of screening.

The operations of Revenio Research Oy, the subsidiary that we established in
December, have been initiated according to plan. Our projects related to
asthma and skin cancer detection technologies progressed according to plan in
Q1. It should be noted, however, that even though both products have been
tested by experts and received excellent assessments, we do not expect a
commercial impact from these products for a few years yet.

From the beginning of May, I will be working from the United States, which
reflects the crucial role of the US market as the largest market area for
health technology. Through our presence in this market area, we will be able
to better support our local distribution network and our own organization,
and make them even better. Local presence is important also in terms of
moving the FDA process forward. The most important reason for my moving to
the US is to build personal relationships with the customer base, our
distributors and physicians in decision-making positions."

General clause

This release contains certain forward-looking statements that are based on
management's current assumptions. Due to their nature, these statements
involve risks and uncertainty, and are sensitive to changes in the economy or
industry.

Revenio Group Corporation
Board of Directors

For further information, please contact:
President&CEO Olli-Pekka Salovaara, tel. +358 40 567 5520
olli-pekka.salovaara@revenio.fi
www.revenio.fi

DISTRIBUTION:
NASDAQ OMX Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish health tech group whose core business is tonometers. The
Revenio Health Tech segment comprises the business operations of Icare
Finland Oy, Revenio Research Oy and Oscare Medical Oy, which specializes in
osteoporosis screening and monitoring. The common denominators of Revenio's
business operations include screening, follow-up and the global need to make
cost savings in health care via preventive measures. Revenio seeks vigorous
growth in health technology, both organically and through acquisitions and
mergers. Revenio aims at developing even more efficient and easily adopted
methods for the early-stage detection of diseases with significance for
public health. The focus of Revenio's screening technology lies on the early
detection of glaucoma, osteoporosis, skin cancer and asthma, and the
monitoring of these during the treatment process.

In 2014, the Revenio Group's net sales totaled MEUR 16.0, with its operating
margin for continuing operations standing at 27.5%. Revenio Group Corporation
has been listed in NASDAQ OMX Helsinki.

Revenio Group Corporation Interim Report Q1 2015
http://hugin.info/151657/R/1913853/684042.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Revenio Group Corporation via Globenewswire

HUG#1913853

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.